Imaging in childhood cancer: A society for pediatric radiology and children's oncology group joint task force report

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages 1253-1260

  Weiser, Daniel A ^a   Kaste, Sue C ^b,c   Siegel, Marilyn J ^d   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnostic imaging; Imaging guidelines; Ionizing radiation

Indexed keywords

ANGIOGENESIS INHIBITOR; ERLOTINIB; FLUORODEOXYGLUCOSE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CHILDHOOD CANCER; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE SURVEILLANCE; EVIDENCE BASED PRACTICE; HEALTH CARE SURVEY; HODGKIN DISEASE; HUMAN; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RADIATION EXPOSURE; REVIEW; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SARCOMA;

ADOLESCENT; ADVISORY COMMITTEES; CHILD; CHILD, PRESCHOOL; DECISION MAKING; DIAGNOSTIC IMAGING; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICAL ONCOLOGY; NEOPLASMS; RADIOLOGY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84879247267     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24533     Document Type: Review

References (91)

1. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27:2328-2338.
2. Linet MS, Wacholder S, Zahm SH. Interpreting epidemiologic research: Lessons from studies of childhood cancer. Pediatrics 2003; 112:218-232.
3. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618-629.
4. Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know. Proc Natl Acad Sci USA 2003; 100:13761-13766.
5. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008; 81:362-378.
6. Brenner D, Elliston C, Hall E, et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289-296.
7. Committee to assess health risks from exposure to low levels of ionizing radiation nrc. health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2. Washington, DC: National Academies Press 2006. xvi, 406 p.
8. Kun LE, Beltran C. Radiation therapy for children: Evolving technologies in the era of ALARA. Pediatr Radiol 2009; 39:S65-S70.
9. Ahmed BA, Connolly BL, Shroff P, et al. Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics 2010; 126:e851-e858.
10. Chong AL, Grant RM, Ahmed BA, et al. Imaging in pediatric patients: Time to think again about surveillance. Pediatr Blood Cancer 2010; 55:407-413.
11. Kaste SC. Imaging challenges: A US perspective on controlling exposure to ionizing radiation in children with cancer. Pediatr Radiol 2009; 39:S74-S79.
12. Preston DL, Shimizu Y, Pierce DA, et al. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003; 160:381-407.
13. Pierce DA, Preston DL. Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 2000; 154:178-186.
14. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: A retrospective cohort study. Lancet 2012; 380:499-505.
15. Brenner DJ. Estimating cancer risks from pediatric CT: Going from the qualitative to the quantitative. Pediatric radiology 2002; 32:228-231.
16. Lautin EM. CT as a cause of cancer: What's old is new again. Am J Roentgenol 2001; 177:717.
17. Nichols AV. In appreciation of prudence. Am J Roentgenol 2001; 177:1218-1219.
18. Brenner DJ, Hall EJ. Computed tomography-An increasing source of radiation exposure. N Engl J Med 2007; 357:2277-2284.
19. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary Cl, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2009_pops09/ based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
20. Commission USNR. Standards for protection against radiation. Vol. 56 FR 23391. Washington, DC: US NRC; 1991.
21. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361:849-857.
22. Voss SD, Reaman GH, Kaste SC, et al. The ALARA concept in pediatric oncology. Pediatr Radiol 2009; 39:1142-1146.
23. Reaman GH. What why and when we image: Considerations for diagnostic imaging and clinical research in the Children's Oncology Group. Pediatr Radiol 2009; 39:S42-S45.
24. Khanna G. Imaging in pediatric bone tumors: Osteosarcoma and ewing sarcoma. In: Santiago Medina L, Applegate KE, Blackmore CC, editors. Evidence-based imaging in pediatrics: Optimizing imaging in pediatric patient care. New York: Springer; 2010. p. 259.
25. Siegel MJ. Pediatric abdominal tumors: Neuroblastoma. In: Santiago Medina L, Applegate KE, Blackmore CC, editors. Evidence-based imaging in pediatrics: Optimizing imaging in pediatric patient care. New York: Springer; 2010. p. 509.
26. Siegel MJ. Pediatric abdominal tumors: Wilms tumor. In: Santiago Medina L, Applegate KE, Blackmore CC, editors. Evidence-based imaging in pediatrics: Optimizing imaging in pediatric patient care. New York: Springer; 2010. p. 525.
27. Lee EY. Imaging evaluation of mediastinal masses in infants and children. In: Santiago Medina L, Applegate KE, Blackmore CC, editors. Evidence-based imaging in pediatrics: Optimizing imaging in pediatric patient care. New York: Springer; 2010. p. 381.
28. Chang AE, Schaner EG, Conkle DM, et al. Evaluation of computed tomography in the detection of pulmonary metastases: A prospective study. Cancer 1979; 43:913-916.
29. Muhm JR, Brown LR, Crowe JK. Detection of pulmonary nodules by computed tomography. Am J Roentgenol 1977; 128:267-270.
30. Schaner EG, Chang AE, Doppman JL, et al. Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: A prospective radiologic-pathologic study. Am J Roentgenol 1978; 131:51-54.
31. Cohen M, Grosfeld J, Baehner R, et al. Lung CT for detection of metastases: Solid tissue neoplasms in children. Am J Roentgenol 1982; 139:895-898.
32. Thomsen HS. Nephrogenic systemic fibrosis: History and epidemiology. Radiol Clin North Am 2009; 47:827-831, vi.
33. AGNIR. 2010 Health Effects of Exposure to Ultrasound and Infrasound. Health Protection Agency, http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1265028759369%3E Accessed 11/30/2012.
34. Hernandez-Pampaloni M, Takalkar A, Yu JQ, et al. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatric Radiol 2006; 36:524-531.
35. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee. Pediatric Blood Cancer 2008; 51:163-170.
36. Gelfand MJ, Parisi MT, Treves ST. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nucl Med 2011; 52:318-322.
37. Treves ST, Davis RT, Fahey FH. Administered radiopharmaceutical doses in children: A survey of 13 pediatric hospitals in North America. J Nucl Med 2008; 49:1024-1027.
38. Treves ST, Parisi MT, Gelfand MJ. Pediatric radiopharmaceutical doses: New guidelines. Radiology 2011; 261:347-349.
39. Krasin MJ, Hudson MM, Kaste SC. Positron emission tomography in pediatric radiation oncology: Integration in the treatment-planning process. Pediatr Radiol 2004; 34:214-221.
40. Willowson KP, Bailey EA, Bailey DL. A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med 2012; 35:49-53.
41. Adamson PC. Imaging in early phase childhood cancer trials. Pediatr Radiol 2009; 39:S38-S41.
42. Wilimas JA, Douglass EC, Magill HL, et al. Significance of pulmonary computed tomography at diagnosis in Wilms' tumor. J Clin Oncol 1988; 6:1144-1146.
43. Green DM, Fernbach DJ, Norkool P, et al. The treatment of Wilms' tumor patients with pulmonary metastases detected only with computed tomography: A report from the National Wilms' Tumor Study. J Clin Oncol 1991; 9:1776-1781.
44. Wilimas JA, Kaste SC, Kauffman WM, et al. Use of chest computed tomography in the staging of pediatric Wilms' tumor: Interobserver variability and prognostic significance. J Clin Oncol 1997; 15:2631-2635.
45. Owens CM, Veys PA, Pritchard J, et al. Role of chest computed tomography at diagnosis in the management of Wilms' tumor: A study by the United Kingdom Children's Cancer Study Group. J Clin Oncol 2002; 20:2768-2773.
46. Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: A report from the Children's Oncology Group. Pediatric Blood Cancer 2012; 59:631-635.
47. Meisel JA, Guthrie KA, Breslow NE, et al. Significance and management of computed tomography detected pulmonary nodules: A report from the National Wilms Tumor Study Group. Int J Radiat Oncol Biol Phys 1999; 44:579-585.
48. Green DM. Use of chest computed tomography for staging and treatment of Wilms' tumor in children. J Clin Oncol 2002; 20:2763-2764.
49. Purz S, Mauz-Korholz C, Korholz D, et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2011; 29:3523-3528.
50. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999; 40:1407-1413.
51. Shulkin BL, Goodin GS, McCarville MB, et al. Bone and [18F]fluorodeoxyglucose positron-emission tomography/computed tomography scanning for the assessment of osseous involvement in Hodgkin lymphoma in children and young adults. Leuk Lymphoma 2009; 50:1794-1802.
52. Kneisl JS, Patt JC, Johnson JC, et al. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 2006; 450:101-104.
53. Ricard F, Cimarelli S, Deshayes E, et al. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011; 36:672-677.
54. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010; 11:184-192.
55. Sammer MB, Shulkin BL, Alessio A, et al. Role of limited whole-body PET/CT in pediatric lymphoma. Am J Roentgenol 2011; 196:1047-1055.
56. Yalcin B, Buyukpamukcu M, Akalan N, et al. Value of surveillance imaging in the management of medulloblastoma. Med Pediatric Oncol 2002; 38:91-97.
57. Mullen EA, Anderson JR, Steacy KJ, et al. The impact of surveillance imaging on overall survival in patients with recurrent Wilms tumor: A report from the Children's Oncology Group. J Clin Oncol 2011; 29:suppl abstract 9536.
58. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med 1994; 330:892-895.
59. Voss SD, Chen L, Constine LS, et al. Surveillance Computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric hodgkin's lymphoma: A report from the Children's Oncology Group. J Clin Oncol 2012; 30:2635-2640.
60. Postovsky S, Barzilai M, Meller I, et al. Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience. J Pediatr Hematol Oncol 2008; 30:189-195.
61. Libby DM, Smith JP, Altorki NK, et al. Managing the small pulmonary nodule discovered by CT. Chest 2004; 125:1522-1529.
62. Biasotti S, Garaventa A, Padovani P, et al. Role of active follow-up for early diagnosis of relapse after elective end of therapies. Pediatr Blood Cancer 2005; 45:781-786.
63. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol 1997; 15:1123-1130.
64. Walter F, Czernin J, Hall T, et al. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatric Hematol/Oncol 2012; 34:131-136.
65. Agrawal AK, Saini N, Gildengorin G, et al. Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies? Pediatr Blood Cancer 2011; 57:620-624.
66. Archibald S, Park J, Geyer JR, et al. Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J 2001; 20:5-10.
67. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427-4438.
68. Ruhnke M, Bohme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82:S141-S148.
69. McCarville MB, Adelman CS, Li C. et al. Typhlitis in childhood cancer. Cancer 2005; 104:380-387.
70. Ojala AE, Lanning FP, Lanning BM. Abdominal ultrasound findings during and after treatment of childhood acute lymphoblastic leukemia. Med Pediatric Oncol 1997; 29:266-271.
71. Deimling GT, Bowman KF, Sterns S, et al. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology 2006; 15:306-320.
72. Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010; 21:2262-2266.
73. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23:8828-8834.
74. Miller E, Metser U, Avrahami G, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006; 30:689-694.
75. Zander T, Scheffler M, Nogova L, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011; 29:1701-1708.
76. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 2009; 27:1906-1914.
77. Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: A compass for a safe navigation in clinical trials? Blood 2012; 120:4913-4920.
78. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006; 6:135-143.
79. Glade Bender J, Yamashiro DJ, Fox E. Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist 2011; 16:1614-1625.
80. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Instit 2000; 92:205-216.
81. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
82. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50:122S-150S.
83. Okuyama C, Ushijima Y, Kubota T, et al. Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun 2002; 23:663-672.
84. Hadj-Djilani NL, Lebtahi NE, Delaloye AB, et al. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 1995; 22:322-329.
85. Kushner BH, Kramer K, Modak S, et al. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009; 27:1041-1046.
86. Satharasinghe K, Trahair TN, Barbaric D, et al. False-positive MIBG scans with normal computed tomography imaging in patients with high-risk neuroblastoma. J Clin Oncol 2009; 27:e233-e234; author reply e235.
87. Claviez A, Kluge R, Mauz-Korholz C, et al. Prognostic impact of early and late 18fluorodeoxyglucose positron emission tomography (FDG-PET) prior to autologous stem cell transplantation in children and adolescents with relapsed or refractory hodgkin lymphoma. ASH Annu Meet Abstr 2011; 118:3108.
88. Institute NC July 12, 2012. Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers. http://www.cancer.gov/cancertopics/causes/radiation/radiation-risks-pediatric-CT%3E Accessed July 12, 2012.
89. Linet MS, Kim KP, Rajaraman P. Children's exposure to diagnostic medical radiation and cancer risk: Epidemiologic and dosimetric considerations. Pediatr Radiol 2009; 39:S4-S426.
90. American Association for Physicists in Medicine. The measurement, reporting and management of radiation dose in CT. MD: College Park; 2008.
91. Singh S, Kalra MK, Shenoy-Bhangle AS, et al. Radiation dose reduction with hybrid iterative reconstruction for pediatric CT. Radiology 2012; 263:537-546.